Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: TechSci Research | PRODUCT CODE: 1372881

Cover Image

PUBLISHER: TechSci Research | PRODUCT CODE: 1372881

Mesenchymal Stem Cells Market, 2028- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product & Services, By Workflow, By Type, By Source of Isolation, By Indication, By Application, By Region, By Competition.

PUBLISHED:
PAGES: 172 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4900
PDF and Excel (Multi-User License)
USD 5900
PDF and Excel (Custom Research License)
USD 8900

Add to Cart

We offer 8 hour analyst time for an additional research. Please contact us for the details.

Global Mesenchymal Stem Cells Market has valued at USD 2.71 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 12.37% through 2028. The global mesenchymal stem cells (MSCs) market has been experiencing remarkable growth in recent years, thanks to advancements in regenerative medicine, increasing awareness of their therapeutic potential, and a rising number of clinical trials. Mesenchymal stem cells, also known as multipotent stromal cells, have garnered significant attention for their unique ability to differentiate into various cell types, making them a valuable resource for treating a wide range of medical conditions.

Mesenchymal stem cells are a type of adult stem cell found in various tissues, including bone marrow, adipose tissue, umbilical cord blood, and dental pulp. They have the ability to differentiate into bone, cartilage, adipose tissue, and other cell types, making them a versatile tool in regenerative medicine. These cells are known for their immunomodulatory properties, low immunogenicity, and anti-inflammatory effects, which contribute to their therapeutic potential in treating a wide range of diseases.

Mesenchymal stem cells have been at the forefront of regenerative medicine. They hold immense potential in tissue repair and regeneration, making them invaluable for treating conditions such as osteoarthritis, cardiovascular diseases, and spinal cord injuries. The rise in clinical trials using MSCs for various applications is a significant driver of market growth. Researchers are exploring their potential in treating COVID-19, diabetes, neurodegenerative disorders, and autoimmune diseases. MSCs are not limited to a specific therapeutic area. Their adaptability and safety profile have led to exploration in diverse fields, including orthopedics, dermatology, and oncology. The global aging population has contributed to the demand for regenerative therapies. As people age, the prevalence of age-related diseases such as osteoarthritis and Alzheimer's disease has increased, further fueling the demand for MSC-based treatments. Increasing investments from both public and private sectors are accelerating research and development efforts in the MSC market. This funding supports the expansion of manufacturing capabilities and clinical trials.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 2.71 Billion
Market Size 2028USD 5.46 Billion
CAGR 2023-202812.37%
Fastest Growing SegmentAutologous
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Chronic Diseases is Driving the Global Mesenchymal Stem Cells Market

The global healthcare landscape is undergoing a significant transformation, primarily due to the rising prevalence of chronic diseases. Chronic diseases, such as diabetes, cardiovascular diseases, arthritis, and neurodegenerative disorders, have become a global health challenge, impacting millions of lives and straining healthcare systems. In response to this growing crisis, researchers and healthcare professionals are turning to innovative therapies, and one promising approach involves the use of mesenchymal stem cells (MSCs). The global mesenchymal stem cells market is witnessing remarkable growth, driven by the increasing demand for regenerative medicine and cell-based therapies to combat chronic diseases.

Chronic diseases are characterized by their long duration and slow progression, making them a significant burden on healthcare systems worldwide. The World Health Organization (WHO) estimates that chronic diseases are responsible for approximately 71% of all global deaths. These conditions not only impact the quality of life for individuals but also result in substantial economic costs due to increased healthcare expenditures and lost productivity.

As the global population continues to age, the risk of developing chronic diseases, such as Alzheimer's disease, Parkinson's disease, and osteoarthritis, increases significantly. Modern lifestyles often involve prolonged periods of inactivity, leading to an increased risk of obesity, type 2 diabetes, and cardiovascular diseases. Poor dietary choices, including excessive consumption of processed foods high in sugar and unhealthy fats, contribute to the development of chronic conditions like diabetes and hypertension. Environmental factors, such as air pollution and exposure to harmful chemicals, can contribute to the development of respiratory diseases and cancers.

Mesenchymal stem cells hold great promise as a therapeutic option for chronic diseases due to their regenerative and immunomodulatory properties. They can be used in several ways to address these conditions. MSCs can differentiate into various cell types, making them valuable in regenerating damaged tissues and organs. They have shown promise in treating conditions like osteoarthritis, where they can stimulate cartilage repair. MSCs possess immunomodulatory properties that can help regulate the immune system's response. This is particularly relevant in autoimmune diseases, where an overactive immune system attacks healthy tissues. MSCs can dampen this response and reduce inflammation. MSCs can be used in tissue engineering to create artificial organs or tissues for transplantation. This has the potential to revolutionize the treatment of diseases like diabetes, where pancreatic tissue can be engineered to produce insulin.

Increasing Investment in Biotechnology is Driving the Global Men's Health Supplements Market

The field of biotechnology has been rapidly advancing, leading to groundbreaking discoveries and innovations in healthcare. One of the most exciting developments is the increased focus on mesenchymal stem cells (MSCs) and their potential applications in regenerative medicine and cell therapy. The global mesenchymal stem cells market is experiencing significant growth, largely attributed to the escalating investments in biotechnology research and development.

The biotechnology sector has witnessed substantial advancements, particularly in the fields of cell biology and genetic engineering. These breakthroughs have enabled researchers to harness the full potential of MSCs for therapeutic purposes. Improved understanding of MSC biology and the development of scalable manufacturing processes have accelerated their clinical translation. Investment in biotechnology research and development has seen a significant uptick in recent years. Both public and private sectors have allocated substantial funds to support research projects exploring the therapeutic applications of MSCs. This funding has been instrumental in advancing clinical trials and bringing promising therapies closer to market approval.

Rising Awareness and Patient Demand is Driving the Global Men's Health Supplements Market

The global mesenchymal stem cells (MSCs) market is experiencing a significant surge in growth, and this phenomenon can be attributed to the rising awareness of the potential therapeutic applications of MSCs and the increasing demand from patients seeking innovative regenerative medicine solutions. Awareness about the therapeutic potential of MSCs has been steadily growing among both healthcare professionals and the general public. Clinical studies and successful cases have highlighted the efficacy of MSC-based therapies in treating conditions like osteoarthritis, autoimmune diseases, and cardiovascular disorders. This heightened awareness has prompted more patients to seek MSC-based treatments. The number of clinical trials involving MSCs has been on the rise, covering a wide range of applications, from orthopedics to cardiology. This surge in clinical research not only validates the potential of MSC-based treatments but also fosters collaborations between research institutions and the pharmaceutical industry. MSCs are no longer limited to regenerating damaged tissues but are increasingly being explored for their immunomodulatory properties. They are being investigated for their potential in treating inflammatory and autoimmune diseases, expanding their market potential.

Key Market Challenges

Regulatory Challenges

One of the foremost challenges in the global MSCs market is the complex and evolving regulatory landscape. Regulatory bodies vary from country to country, making it difficult for companies to navigate the approval process for MSC-based therapies. Achieving compliance with various regulations, including Good Manufacturing Practices (GMP), is a costly and time-consuming endeavor. Harmonizing these regulations and fostering a globally recognized framework is essential to accelerate market growth.

Sourcing and Quality Control

The reliable sourcing of high-quality MSCs is a significant concern in the industry. Ensuring the consistency, purity, and potency of MSCs is critical for therapeutic success. Challenges arise in obtaining consistent donor tissues and maintaining cell quality during expansion and storage. Innovations in cell culture techniques and standardized protocols can help address these concerns.

Scalability

As the demand for MSC-based therapies increases, scalability becomes a crucial issue. Expanding MSC production to meet the growing market demand while maintaining cell quality is a substantial challenge. Developing cost-effective and scalable manufacturing processes is essential to avoid supply shortages and reduce the overall cost of these therapies.

Competition and Intellectual Property

The MSCs market is highly competitive, with numerous companies and research institutions actively pursuing MSC-based therapies. Intellectual property disputes and patent wars are not uncommon, hindering innovation and collaboration within the industry. Establishing clear guidelines and mechanisms for intellectual property sharing can help overcome these challenges.

Clinical Trial Complexities

Conducting clinical trials for MSC-based therapies presents unique challenges. The need for large, diverse patient populations, long-term follow-ups, and standardized outcome measures can be logistically and financially demanding. Collaboration between industry stakeholders, academia, and regulatory bodies can streamline the clinical trial process and facilitate data sharing.

Ethical Concerns

The ethical use of MSCs remains a contentious issue. The source of MSCs, often derived from bone marrow or adipose tissue, raises questions about donor consent, tissue sourcing, and equitable access to therapies. Ensuring transparency, informed consent, and ethical practices in research and clinical applications is paramount to maintaining public trust.

Cost and Reimbursement

MSC-based therapies are often expensive due to the complexities of production, regulation, and quality control. Securing reimbursement from healthcare systems and insurance providers can be challenging, limiting patient access to these innovative treatments. Collaborative efforts between stakeholders are essential to address pricing and reimbursement issues.

Market Fragmentation

The global MSCs market is fragmented, with numerous small and medium-sized enterprises (SMEs) operating alongside large pharmaceutical companies. Consolidation within the industry can lead to better resource utilization, streamlined research efforts, and improved access to capital for smaller players.

Key Market Trends

Technological Advancements

The field of regenerative medicine has been revolutionized in recent years, thanks to the remarkable progress in stem cell research and the development of cutting-edge technologies. Among the various types of stem cells, mesenchymal stem cells (MSCs) have garnered significant attention for their potential to treat a wide range of medical conditions. The global mesenchymal stem cells market is experiencing rapid growth, fueled by the convergence of scientific breakthroughs and technological advancements.

The culturing of MSCs has become more efficient and reproducible through the use of advanced bioreactors, 3D scaffolds, and microfluidic systems. These technologies have enabled researchers to produce large quantities of high-quality MSCs for therapeutic purposes. Genetic modification techniques, such as CRISPR-Cas9, have allowed scientists to enhance the therapeutic potential of MSCs. This includes tailoring MSCs to express specific proteins or factors that can boost their regenerative properties or modulate immune responses. Innovations in biomaterials and drug delivery systems have enabled the targeted and controlled delivery of MSCs to specific sites within the body. This has improved the efficacy and safety of MSC-based therapies. Automation and robotics are streamlining the manufacturing process of MSC-based products, reducing costs, and ensuring consistent product quality. This is essential for the scalability of MSC therapies. Advanced imaging techniques, such as magnetic resonance imaging (MRI) and bioluminescent imaging, allow researchers to track the fate of transplanted MSCs within the body, optimizing treatment strategies and improving patient outcomes.

Segmental Insights

Workflow Insights

Based on the category of Workflow, the bioavailability & bioequivalence studies segment emerged as the dominant player in the global market for Mesenchymal Stem Cells in 2022. Culture and cryopreservation are critical for the maintenance and expansion of MSCs. MSCs are typically isolated from various sources, such as bone marrow, adipose tissue, or umbilical cord blood. Once isolated, they need to be cultured to grow in sufficient numbers for therapeutic applications. Cryopreservation allows for long-term storage of these cells without significant loss of their therapeutic properties. This process ensures a stable supply of MSCs for research and clinical use. The culture and cryopreservation segments are closely tied to research and development efforts in the field of regenerative medicine and cell-based therapies. Scientists and pharmaceutical companies conduct extensive research to understand the potential therapeutic applications of MSCs, and this often involves maintaining large stocks of these cells in culture and cryopreservation. Many organizations and institutions maintain cell banks, which include MSCs, for future research and clinical applications. These cell banks require robust culture and cryopreservation protocols to ensure the long-term viability of the cells. This infrastructure is essential for the scalability and availability of MSCs for various applications. MSCs have shown promise in treating various medical conditions, including orthopedic disorders, autoimmune diseases, and tissue regeneration. Clinical trials and therapeutic applications often rely on the availability of high-quality MSCs, which are stored and transported using cryopreservation methods.

Type Insights

The Allogeneic segment is projected to experience rapid growth during the forecast period. Allogeneic MSCs are derived from healthy donors and can be expanded in large quantities in a controlled environment. This makes them more readily available in sufficient quantities to meet the growing demand in clinical applications and research. Allogeneic MSCs can be produced under strict quality control measures, ensuring consistency in cell characteristics, potency, and safety. This is critical for applications in regenerative medicine and cell-based therapies. Autologous MSCs, which are obtained from a patient's own tissue, may exhibit variability in quality and potency due to the patient's age and health condition. Allogeneic MSCs, on the other hand, can be standardized, reducing variability.

Regional Insights

North America emerged as the dominant player in the global Mesenchymal Stem Cells market in 2022, holding the largest market share in terms of value. North America, particularly the United States, has a well-developed and advanced healthcare and biotechnology sector. The region is home to numerous research institutions, universities, and pharmaceutical companies that invest heavily in stem cell research and development. This extensive R&D infrastructure has contributed to advancements in MSC therapies and products. The regulatory environment in North America has been relatively supportive of stem cell research and clinical trials. Organizations like the Food and Drug Administration (FDA) in the United States have established clear guidelines for the development and use of MSC-based therapies, which has given confidence to investors and researchers. North America has attracted significant investments in the field of regenerative medicine, including MSC research. Private and public funding sources, venture capital, and grants have played a crucial role in supporting research and development activities, clinical trials, and commercialization efforts in the region.

Key Market Players

  • Thermo Fisher Scientific, Inc
  • Cell Applications, Inc
  • Axol Biosciences Ltd
  • Cytori Therapeutics Inc
  • STEMCELL Technologies
  • Cyagen Biosciences
  • Celprogen Inc
  • BrainStorm Cell Limited
  • Stemedica Cell Technologies Inc
  • Merck KGaA (MilliporeSigma)
  • PromoCell GmbH

Report Scope:

In this report, the Global Mesenchymal Stem Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Mesenchymal Stem Cells Market, By Product & Services:

Product

Services

Mesenchymal Stem Cells Market, By Workflow:

Cell Sourcing & Isolation

Culture & Cryopreservation

Differentiation

Characterization

Mesenchymal Stem Cells Market, By Type:

  • Autologous
  • Allogeneic

Mesenchymal Stem Cells Market, By Source of Isolation:

  • Bone Marrow
  • Cord Blood
  • Peripheral Blood
  • Fallopian Tube
  • Fetal Liver
  • Lung
  • Adipose Tissues

Mesenchymal Stem Cells Market, By Indication:

  • Bone And Cartilage Repair
  • Cardiovascular Disease
  • Inflammatory And Immunological Diseases
  • Liver Diseases
  • Cancer
  • GvHD
  • Others

Mesenchymal Stem Cells Market, By Application:

  • Disease Modelling
  • Drug Development & Discovery
  • Stem Cell Banking
  • Tissue Engineering
  • Toxicology Studies
  • Others

Mesenchymal Stem Cells Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Mesenchymal Stem Cells Market.

Available Customizations:

  • Global Mesenchymal Stem Cells market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Product Code: 16246

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

4. Voice of Customer

5. Global Mesenchymal Stem Cells Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product & Services (Products(Cells & Cell Lines, Kits, Media, & Reagents, Others), Services)
    • 5.2.2. By Workflow ( Cell Sourcing & Isolation, Culture & Cryopreservation, Differentiation, Characterization)
    • 5.2.3. By Type ( Autologous, Allogeneic)
    • 5.2.4. By Source of Isolation( Bone Marrow, Cord Blood, Peripheral Blood, Fallopian Tube, Fetal Liver, Lung, Adipose Tissues)
    • 5.2.5. By Indication (Bone And Cartilage Repair, Cardiovascular Disease, Inflammatory And Immunological Diseases, Liver Diseases, Cancer, GvHD, Others)
    • 5.2.6. By Application ( Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies, Others)
    • 5.2.7. By Region
    • 5.2.8. By Company (2022)
  • 5.3. Market Map

6. North America Mesenchymal Stem Cells Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product & Services
    • 6.2.2. By Workflow
    • 6.2.3. By Type
    • 6.2.4. By Source of Isolation
    • 6.2.5. By Indication
    • 6.2.6. By Application
    • 6.2.7. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Mesenchymal Stem Cells Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product & Services
        • 6.3.1.2.2. By Workflow
        • 6.3.1.2.3. By Type
        • 6.3.1.2.4. By Source of Isolation
        • 6.3.1.2.5. By Indication
        • 6.3.1.2.6. By Application
    • 6.3.2. Canada Mesenchymal Stem Cells Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product & Services
        • 6.3.2.2.2. By Workflow
        • 6.3.2.2.3. By Type
        • 6.3.2.2.4. By Source of Isolation
        • 6.3.2.2.5. By Indication
        • 6.3.2.2.6. By Application
    • 6.3.3. Mexico Mesenchymal Stem Cells Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product & Services
        • 6.3.3.2.2. By Workflow
        • 6.3.3.2.3. By Type
        • 6.3.3.2.4. By Source of Isolation
        • 6.3.3.2.5. By Indication
        • 6.3.3.2.6. By Application

7. Europe Mesenchymal Stem Cells Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product & Services
    • 7.2.2. By Workflow
    • 7.2.3. By Type
    • 7.2.4. By Source of Isolation
    • 7.2.5. By Indication
    • 7.2.6. By Application
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Mesenchymal Stem Cells Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product & Services
        • 7.3.1.2.2. By Workflow
        • 7.3.1.2.3. By Type
        • 7.3.1.2.4. By Source of Isolation
        • 7.3.1.2.5. By Indication
        • 7.3.1.2.6. By Application
    • 7.3.2. United Kingdom Mesenchymal Stem Cells Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product & Services
        • 7.3.2.2.2. By Workflow
        • 7.3.2.2.3. By Type
        • 7.3.2.2.4. By Source of Isolation
        • 7.3.2.2.5. By Indication
        • 7.3.2.2.6. By Application
    • 7.3.3. Italy Mesenchymal Stem Cells Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Product & Services
        • 7.3.3.2.2. By Workflow
        • 7.3.3.2.3. By Type
        • 7.3.3.2.4. By Source of Isolation
        • 7.3.3.2.5. By Indication
        • 7.3.3.2.6. By Application
    • 7.3.4. France Mesenchymal Stem Cells Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product & Services
        • 7.3.4.2.2. By Workflow
        • 7.3.4.2.3. By Type
        • 7.3.4.2.4. By Source of Isolation
        • 7.3.4.2.5. By Indication
        • 7.3.4.2.6. By Application
    • 7.3.5. Spain Mesenchymal Stem Cells Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product & Services
        • 7.3.5.2.2. By Workflow
        • 7.3.5.2.3. By Type
        • 7.3.5.2.4. By Source of Isolation
        • 7.3.5.2.5. By Indication
        • 7.3.5.2.6. By Application

8. Asia-Pacific Mesenchymal Stem Cells Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product & Services
    • 8.2.2. By Workflow
    • 8.2.3. By Type
    • 8.2.4. By Source of Isolation
    • 8.2.5. By Indication
    • 8.2.6. By Application
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Mesenchymal Stem Cells Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product & Services
        • 8.3.1.2.2. By Workflow
        • 8.3.1.2.3. By Type
        • 8.3.1.2.4. By Source of Isolation
        • 8.3.1.2.5. By Indication
        • 8.3.1.2.6. By Application
    • 8.3.2. India Mesenchymal Stem Cells Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product & Services
        • 8.3.2.2.2. By Workflow
        • 8.3.2.2.3. By Type
        • 8.3.2.2.4. By Source of Isolation
        • 8.3.2.2.5. By Indication
        • 8.3.2.2.6. By Application
    • 8.3.3. Japan Mesenchymal Stem Cells Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product & Services
        • 8.3.3.2.2. By Workflow
        • 8.3.3.2.3. By Type
        • 8.3.3.2.4. By Source of Isolation
        • 8.3.3.2.5. By Indication
        • 8.3.3.2.6. By Application
    • 8.3.4. South Korea Mesenchymal Stem Cells Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product & Services
        • 8.3.4.2.2. By Workflow
        • 8.3.4.2.3. By Type
        • 8.3.4.2.4. By Source of Isolation
        • 8.3.4.2.5. By Indication
        • 8.3.4.2.6. By Application
    • 8.3.5. Australia Mesenchymal Stem Cells Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product & Services
        • 8.3.5.2.2. By Workflow
        • 8.3.5.2.3. By Type
        • 8.3.5.2.4. By Source of Isolation
        • 8.3.5.2.5. By Indication
        • 8.3.5.2.6. By Application

9. South America Mesenchymal Stem Cells Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product & Services
    • 9.2.2. By Workflow
    • 9.2.3. By Type
    • 9.2.4. By Source of Isolation
    • 9.2.5. By Indication
    • 9.2.6. By Application
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Mesenchymal Stem Cells Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product & Services
        • 9.3.1.2.2. By Workflow
        • 9.3.1.2.3. By Type
        • 9.3.1.2.4. By Source of Isolation
        • 9.3.1.2.5. By Indication
        • 9.3.1.2.6. By Application
    • 9.3.2. Argentina Mesenchymal Stem Cells Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product & Services
        • 9.3.2.2.2. By Workflow
        • 9.3.2.2.3. By Type
        • 9.3.2.2.4. By Source of Isolation
        • 9.3.2.2.5. By Indication
        • 9.3.2.2.6. By Application
    • 9.3.3. Colombia Mesenchymal Stem Cells Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product & Services
        • 9.3.3.2.2. By Workflow
        • 9.3.3.2.3. By Type
        • 9.3.3.2.4. By Source of Isolation
        • 9.3.3.2.5. By Indication
        • 9.3.3.2.6. By Application

10. Middle East and Africa Mesenchymal Stem Cells Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product & Services
    • 10.2.2. By Workflow
    • 10.2.3. By Type
    • 10.2.4. By Source of Isolation
    • 10.2.5. By Indication
    • 10.2.6. By Application
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Mesenchymal Stem Cells Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product & Services
        • 10.3.1.2.2. By Workflow
        • 10.3.1.2.3. By Type
        • 10.3.1.2.4. By Source of Isolation
        • 10.3.1.2.5. By Indication
        • 10.3.1.2.6. By Application
    • 10.3.2. Saudi Arabia Mesenchymal Stem Cells Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product & Services
        • 10.3.2.2.2. By Workflow
        • 10.3.2.2.3. By Type
        • 10.3.2.2.4. By Source of Isolation
        • 10.3.2.2.5. By Indication
        • 10.3.2.2.6. By Application
    • 10.3.3. UAE Mesenchymal Stem Cells Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product & Services
        • 10.3.3.2.2. By Workflow
        • 10.3.3.2.3. By Type
        • 10.3.3.2.4. By Source of Isolation
        • 10.3.3.2.5. By Indication
        • 10.3.3.2.6. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition
  • 12.2. Product Development
  • 12.3. Recent Developments

13. Global Mesenchymal Stem Cells Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Age Group Offerings
  • 14.3. Recent Developments
  • 14.4. Key Personnel
  • 14.5. SWOT Analysis
    • 14.5.1. Thermo Fisher Scientific, Inc
    • 14.5.2. Cell Applications, Inc
    • 14.5.3. Axol Biosciences Ltd
    • 14.5.4. Cytori Therapeutics Inc
    • 14.5.5. STEMCELL Technologies
    • 14.5.6. Cyagen Biosciences
    • 14.5.7. Celprogen Inc
    • 14.5.8. BrainStorm Cell Limited
    • 14.5.9. Stemedica Cell Technologies Inc
    • 14.5.10. Merck KGaA (MilliporeSigma)
    • 14.5.11. PromoCell GmbH

15. Strategic Recommendations

16. About Us & Disclaimer

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!